Weekly Analysts’ Ratings Changes for Kala Pharmaceuticals (KALA)

A number of firms have modified their ratings and price targets on shares of Kala Pharmaceuticals (NASDAQ: KALA) recently:

  • 10/17/2018 – Kala Pharmaceuticals was given a new $32.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 10/16/2018 – Kala Pharmaceuticals was given a new $51.00 price target on by analysts at Wedbush. They now have a “buy” rating on the stock.
  • 10/11/2018 – Kala Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $9.25 price target on the stock. According to Zacks, “Kala Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles technology. The Company designs proprietary drug delivery technology to penetrate mucosal tissue such as the eyes, lungs, gastrointestinal tracts and the female reproductive systems. Kala Pharmaceuticals, Inc. is based in Waltham, United States. “
  • 10/10/2018 – Kala Pharmaceuticals was given a new $51.00 price target on by analysts at Wedbush. They now have a “buy” rating on the stock.
  • 10/4/2018 – Kala Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
  • 10/4/2018 – Kala Pharmaceuticals had its “buy” rating reaffirmed by analysts at Wells Fargo & Co. They now have a $15.00 price target on the stock, down previously from $19.00.
  • 9/11/2018 – Kala Pharmaceuticals was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 9/10/2018 – Kala Pharmaceuticals was given a new $37.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock. They wrote, “Our 12-month target is derived from a market value of the firm at $1.1B, which includes a discounted cash flow-based asset value of $1.1B for INVELTYS (100% probability of success) and KPI-121 0.25% (65% probability of success), with a 15% discount rate and 0.5% terminal growth rate.””
  • 8/26/2018 – Kala Pharmaceuticals was given a new $51.00 price target on by analysts at Wedbush. They now have a “buy” rating on the stock.
  • 8/24/2018 – Kala Pharmaceuticals had its price target raised by analysts at HC Wainwright from $35.00 to $37.00. They now have a “buy” rating on the stock.
  • 8/23/2018 – Kala Pharmaceuticals had its “buy” rating reaffirmed by analysts at Wells Fargo & Co.

NASDAQ:KALA opened at $9.86 on Thursday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 9.79 and a current ratio of 9.79. Kala Pharmaceuticals Inc has a one year low of $7.60 and a one year high of $22.10. The company has a market cap of $242.73 million, a P/E ratio of -1.69 and a beta of -1.07.

Kala Pharmaceuticals (NASDAQ:KALA) last posted its earnings results on Thursday, August 9th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.50) by ($0.10). On average, analysts expect that Kala Pharmaceuticals Inc will post -2.19 earnings per share for the current fiscal year.

In other news, Director Ra Capital Healthcare Fund Lp purchased 2,424,242 shares of the company’s stock in a transaction dated Wednesday, October 3rd. The shares were purchased at an average price of $8.25 per share, for a total transaction of $19,999,996.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Gregory Grunberg purchased 606,060 shares of the company’s stock in a transaction dated Friday, October 5th. The stock was purchased at an average price of $8.25 per share, for a total transaction of $4,999,995.00. The disclosure for this purchase can be found here. 35.58% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Bank of New York Mellon Corp lifted its position in shares of Kala Pharmaceuticals by 23.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 41,327 shares of the company’s stock worth $568,000 after purchasing an additional 7,784 shares during the period. Paloma Partners Management Co acquired a new position in shares of Kala Pharmaceuticals in the 2nd quarter worth approximately $152,000. Rhumbline Advisers acquired a new position in shares of Kala Pharmaceuticals in the 2nd quarter worth approximately $148,000. Wedbush Securities Inc. lifted its position in shares of Kala Pharmaceuticals by 81.6% in the 2nd quarter. Wedbush Securities Inc. now owns 56,420 shares of the company’s stock worth $775,000 after purchasing an additional 25,350 shares during the period. Finally, Alps Advisors Inc. acquired a new position in shares of Kala Pharmaceuticals in the 2nd quarter worth approximately $489,000. Hedge funds and other institutional investors own 72.19% of the company’s stock.

Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. Its product candidates include KPI-121 1.0%, which has completed Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; INVELTYS that has completed Phase III clinical trials for the temporary relief of the signs and symptoms of dry eye disease; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases.

Further Reading: How to interpret a stock’s beta number

Receive News & Ratings for Kala Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply